The Study
Long-term effects of weight-reducing drugs in people with hypertension.
This study looked at many different experiments where people with high blood pressure took weight-loss pills or fake pills. It found that some pills might make people feel worse, but we’re not sure if they help people live longer or have fewer heart problems because not enough people had those serious events in the studies.
Analysis score
Maximum 100 for a systematic review with meta-analysis.
Where the score came from
Scientists looked at 8 studies to see if weight-loss drugs help people with high blood pressure avoid heart attacks or death.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 559 / 100
Quality score
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Even though these drugs help lose weight and lower blood pressure a little, we don't know if they actually prevent heart attacks or death — and they may cause more side effects.
- 2Losing 1 kg lowers blood pressure by 1 mm Hg.
- 3Orlistat causes more serious side effects.
- 4Phentermine/topiramate and naltrexone/bupropion cause more side effects overall.
- 5No drug showed clear benefit for preventing death or heart problems.
- 6Semaglutide and tirzepatide had no safety data.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
The Cochrane database of systematic reviews
Year
2026
Authors
U. Spary-Kainz, N. Posch, C. Radl-Karimi, K. Jeitler, C. Krenn, A. Siebenhofer, Andrea Berghold, K. Horvath, Sebastian Winterholer, T. Semlitsch
Related Content
Claims (6)
Losing one kilogram of body weight lowers systolic blood pressure by about 1 mm Hg.
In adults with essential hypertension, phentermine/topiramate and naltrexone/bupropion are linked to higher rates of adverse events compared to placebo, with risk ratios of 1.13 and 1.69, while orlistat shows no clear difference in adverse event rates.
Orlistat, phentermine/topiramate, and naltrexone/bupropion do not meaningfully change the risk of death or cardiovascular events in adults with high blood pressure. There is no available data on semaglutide or tirzepatide for these outcomes.
There is no available data on death rates, heart-related illnesses, or serious side effects for semaglutide or tirzepatide in adults with high blood pressure, even though these drugs are approved for weight loss and widely used.
In adults with essential hypertension, orlistat increases the risk of serious adverse events compared to placebo, phentermine/topiramate does not increase risk, and naltrexone/bupropion slightly increases risk, based on clinical trial data; however, data on all adverse events for orlistat and phentermine/topiramate is not conclusive.
Studies on weight-loss drugs for people with high blood pressure are limited because most trials are funded by drug companies, do not report results separately for hypertensive patients, and do not follow participants long enough to see effects on heart disease.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.